Denmark-based Bavarian Nordic has signed an agreement to acquire rabies and tick-borne encephalitis (TBE) vaccines from GlaxoSmithKline in a deal valued at around €796m ($888m).
TriPharm Services, a new contract development and manufacturing organization (CDMO), is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment.
Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the US for oral use.
Swiss pharmaceutical company Acino has agreed to acquire Takeda’s select over-the-counter (OTC) and prescription pharmaceutical assets in multiple Near East, Middle East and Africa (NEMEA) countries for a total value of more than $200m.
Thermo Fisher Scientific has launched a new handheld X-ray fluorescence analyser called IonicX XRF Analyzer to help pharmaceutical and biopharmaceutical manufacturers to verify the identity of ionic salts in warehouses within seconds.
Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialised CEQUA (cyclosporine ophthalmic solution) 0.09% in the US.
French pharma company Servier has acquired cancer drug Pixuvri (pixantrone) from US-based CTI BioPharma for an undisclosed price in a move to strengthen its oncology portfolio.
Celltrion announced that it is launching Temixy in the US, which were approved in November by US Food and Drug Administration (FDA).
US-based Amgen has agreed to acquire Celgene’s psoriasis drug Otezla (apremilast) and certain related assets and liabilities for $13.4bn (£10.9bn) in cash.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.